Challenges in ASCVD reduction and TG-related risk10' education - Sep. 20, 2023 - Erik Stroes, MD, PhD - Amsterdam, The Netherlands
Video navigation menu
- Residual risk 0:14
- Triglyceride-rich lipoproteins and atherogenesis 1:13
- Intervention trials 4:58
- New agents 6:42
This lecture by Erik Stroes was part of the EBAC-accredited symposium "Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl" at the ESC congress 2023.
Prof. Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Center in Amsterdam, The Netherlands.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Amarin.